Rheumatoid Arthritis News

The FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe atopic dermatitis among patients aged 12 years and older, according to a press release.

The WHO has issued a “strong recommendation” for baricitinib, in combination with corticosteroids, in the treatment of patients with severe or critical COVID-19.

Just 0.7% of fully vaccinated patients with inflammatory rheumatic and musculoskeletal disease experience a breakthrough COVID-19 infection, while only 4.4% demonstrate disease flare reactions, according to data.

Patients with rheumatoid arthritis, but not psoriatic arthritis or ulcerative colitis, are at a greater risk for severe or critical COVID-19 versus those with COVID-19 alone, according to data published in The Journal of Rheumatology.

In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable biosimilar to AbbVie’s blockbuster drug, Humira — but, as rivals scramble for second place, will the designation be worth the price?

Proactive therapeutic drug monitoring sustained disease control without disease worsening among patients with immune-mediated inflammatory diseases undergoing infliximab maintenance therapy, according to study results.

A machine learning model combining pharmacogenomic biomarkers with baseline DAS28 joint count predicted methotrexate response in early rheumatoid arthritis, according to data published in Arthritis Care & Research.

Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.

DMARD interruptions in patients with autoimmune rheumatic diseases increased more than 80% between December 2020 and May 2021, leading to higher rates of self-reported flares, according to data published in Arthritis Care & Research.

Rheumatoid arthritis-related mortality rates are declining, but death rates related to rheumatoid arthritis-interstitial lung disease remain stable for adults younger than 65 years, researchers reported.